证券日报网讯津药药业（600488）11月12日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司股东数为38950户。 ...

Policy Developments - Jiangxi Province is promoting the development of brain-computer interface medical devices, emphasizing the need for regulatory compliance and collaboration among industry players to seize opportunities in emerging technologies [1] - The market for brain-computer interface medical devices is noted to have significant potential, with a strong development momentum in Jiangxi Province [1] Medical Device Approvals - In October, the National Medical Products Administration approved 204 medical device products, including 173 domestic Class III devices, 10 imported Class III devices, and 21 imported Class II devices [2] Pharmaceutical Logistics - The Shanghai Municipal Drug Administration encourages the development of modern pharmaceutical logistics, advocating for improved storage and management systems to enhance operational efficiency and reduce costs [3] Drug Approvals - Fangsheng Pharmaceutical announced that its Indobufen tablets received a drug registration certificate from the National Medical Products Administration, allowing for production [4] - Saito Bio's application for the chemical raw material drug Mometasone Furoate has been approved, indicating its use in treating asthma and skin conditions [5] - Tianyao Pharmaceutical received a drug registration certificate for Metoclopramide injection, which is used for treating nausea and vomiting [6] Capital Market Activities - Yingsi Intelligent submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for its AI-driven drug development initiatives [7][8] - Rejuve Bio plans to repurchase shares worth between 100 million and 200 million yuan to support employee stock ownership plans [9] Industry Developments - AstraZeneca's Baxdrostat demonstrated significant reductions in 24-hour average systolic blood pressure in treatment-resistant hypertension patients during the Bax24 Phase III trial, achieving a reduction of 14.0 mmHg compared to placebo [10][11] - The drug showed good overall tolerability and consistent safety profiles, with a notable percentage of patients achieving target blood pressure levels [11] - Maiwei Bio's IL-11 monoclonal antibody 9MW3811 received approval for Phase II clinical trials targeting pathological scars, marking it as the first IL-11 targeted drug to enter clinical trials for this indication [12] - Aiwei Technology's subsidiary obtained a medical institution practice license, enabling it to provide third-party medical testing services [13] - Anke Bio signed an exclusive agency framework agreement with Boshengji for the PA3-17 injection product, aimed at enhancing its product portfolio in the innovative drug market [14][15]

Group 1 - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., received a drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [1] - Metoclopramide Hydrochloride Injection is primarily used as an antiemetic for various conditions including chemotherapy, radiotherapy, and postoperative nausea [1] - The drug registration application was submitted in December 2023 and the certificate was obtained in November 2025, with a total R&D investment of approximately 5.9 million yuan [1] Group 2 - The domestic sales figures for Metoclopramide Hydrochloride Injection are projected to be 142 million yuan in 2023 and 118 million yuan in 2024 [2] - The approval of this drug is expected to enhance the company's formulation product portfolio and positively impact its performance in the domestic market [3]

证券代码：600488 证券简称：津药药业 编号：2025-066 三、同类药品市场情况 根据米内网全国放大版的医院数据（含城市公立医院、县级公立医院、城市药 店、网上药店、城市社区医院、乡镇卫生院）显示，盐酸甲氧氯普胺注射液 2023 年、 2024 年国内销售额分别 1.42 亿元、1.18 亿元。 四、影响及风险提示 津药药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司湖北津药药业股份有 限公司（以下简称"湖北津药"）收到国家药品监督管理局核准签发的盐酸甲氧氯 普胺注射液（以下简称 "该药品"或"本品"）的《药品注册证书》。现将相关情况公 告如下： 1 / 2 药品名称 盐酸甲氧氯普胺注射液 剂型 注射剂 注册分类 化学药品 3 类 药品注册标准编号 YBH25362025 规格 2ml:10mg（按 C₁₄H₂₂ClN₃O₂•HCl 计） 受理号 CYHS2303377 证书编号 2025S03273 药品批准 ...

Core Viewpoint - The company, Tianyao Pharmaceutical (600488.SH), announced that its subsidiary, Hubei Tianyao Pharmaceutical Co., Ltd., has received the drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [1] Group 1 - The approved drug, Metoclopramide Hydrochloride Injection, is primarily used as an antiemetic for various conditions including chemotherapy, radiotherapy, surgery, and brain injuries [1] - The medication is indicated for symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic disorders, and uremia [1] - It also aids in facilitating duodenal intubation prior to diagnostic procedures and helps reduce nausea and vomiting during gastrointestinal barium X-ray examinations [1]

Core Viewpoint - Tianyao Pharmaceutical (600488) announced that its subsidiary, Hubei Tianyao Pharmaceutical Co., Ltd., received the drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for a key product in its portfolio [1] Company Summary - Tianyao Pharmaceutical's subsidiary has been granted approval for Metoclopramide Hydrochloride Injection, which is primarily used as an antiemetic [1] - The injection is indicated for various conditions including chemotherapy, radiotherapy, surgery, and other medical situations that may cause nausea and vomiting [1] - The product also aids in diagnostic procedures such as duodenal intubation and enhances the passage of barium during gastrointestinal X-ray examinations [1] Industry Summary - The approval of Metoclopramide Hydrochloride Injection highlights the ongoing demand for antiemetic medications in the healthcare sector, particularly in oncology and gastroenterology [1] - This development may enhance the competitive positioning of Tianyao Pharmaceutical within the pharmaceutical industry, especially in the antiemetic market segment [1]

Core Viewpoint - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Methoclopramide Hydrochloride Injection, which is expected to positively impact the company's performance and market expansion in the domestic formulation sector [1] Group 1 - The approved drug is classified as a Class 3 chemical drug and has passed the consistency evaluation of quality and efficacy for generic drugs [1] - The approval enhances the company's formulation product portfolio, which is anticipated to contribute positively to the company's performance [1] - The development, production, and sales of pharmaceuticals are subject to significant uncertainties due to national policies and market conditions [1]

Core Viewpoint - The company, Tianyao Pharmaceutical (600488.SH), announced that its subsidiary, Hubei Tianyao Pharmaceutical Co., Ltd., has received the drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [1] Group 1: Product Information - Metoclopramide Hydrochloride Injection is an antiemetic drug primarily used for nausea and vomiting caused by chemotherapy, radiotherapy, surgery, and other medical conditions [1] - The drug is also indicated for symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic disorders, and uremia [1] - Additionally, it aids in facilitating duodenal intubation and reduces nausea and vomiting during gastrointestinal barium X-ray examinations [1]

Core Viewpoint - The company has received approval for the drug Methochlorpromazine Hydrochloride Injection, which is primarily used as an antiemetic for various medical conditions [1] Group 1: Product Approval - The subsidiary Hubei Jinyao Pharmaceutical Co., Ltd. has obtained the Drug Registration Certificate from the National Medical Products Administration for Methochlorpromazine Hydrochloride Injection [1] - This injection is indicated for use in chemotherapy, radiotherapy, surgery, and conditions such as brain injuries and drug-induced vomiting [1] Group 2: Medical Applications - Methochlorpromazine Hydrochloride Injection is used for symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic diseases, and uremia [1] - It aids in diagnostic procedures such as duodenal intubation and reduces nausea during gastrointestinal barium X-ray examinations [1]

Core Viewpoint - Tianyao Pharmaceutical stated that as of October 31, 2025, the number of shareholders will be 38,934 [2] Summary by Category - Company Information - Tianyao Pharmaceutical has confirmed the projected number of shareholders to be 38,934 by the end of October 2025 [2]